Satellos Bioscience
Satellos Bioscience is a clinical-stage biotechnology company developing novel small-molecule therapies to treat degenerative muscle diseases, with lead candidate SAT-3247 in Phase 2 development for Duchenne muscular dystrophy. The company reported six-month interim data from the TRAILHEAD study in July 2026 showing reduced muscle-fat fraction and improved biomarker signals, and received FDA Fast Track designation for SAT-3247 in June 2026. Satellos is dual-listed on Nasdaq and the TSX and reported cash and equivalents of approximately Cdn $97.5 million as of Q1 2026 with cash runway through 2027.
Company Info
Upcoming Milestones & Key Dates
Additional Phase 2 BASECAMP and TRAILHEAD data expected
Phase 2 BASECAMP pediatric enrollment completion target
Clinical Development Pipeline
SAT-3247
Target: Muscle regeneration / dystrophin-independent pathwayRecent News
No recent news updates available for this company.
Leadership Team
Frank Gleeson
President and Chief Executive Officer
Liz Williams
Chief Financial Officer
Careers & Job Openings